Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis.

ABSTRACT:

Background

[corrected] Multiple Sclerosis has two clinical phases reflecting distinct but inter-related pathological processes: focal inflammation drives the relapse-remitting stage and neurodegeneration represents the principal substrate of secondary progression. In contrast to the increasing number of effective anti-inflammatory disease modifying treatments for relapse-remitting disease, the absence of therapies for progressive disease represents a major unmet clinical need. This raises the unanswered question of whether elimination of clinical relapses will prevent subsequent progression and if so how early in the disease course should treatment be initiated. Experimental autoimmune encephalomyelitis in the Biozzi ABH mouse recapitulates the clinical and pathological features of

SUBMITTER: Hampton DW 

PROVIDER: S-EPMC3895761 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature